Targeting VEGF in lung cancer

Bibliography

• Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61:212-36
   PubMed Web of Science ®Google Scholar
• Clinical practice guidelines in Oncology, Non-small cell lung cancer.. V.2.2012. Foert Washington,PA: National Comprehensive Cancer Network, 2011. Available from: http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf [Last accessed 28 February 2012]
   Google Scholar
• Park JO, Kim SW, Ahn JS, Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer. J Clin Oncol 2007;25:5233-9
   PubMed Web of Science ®Google Scholar
• Schiller JH, Harrington D, Belani CP, Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-8
   PubMed Web of Science ®Google Scholar
• Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76
   PubMed Web of Science ®Google Scholar
• Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23:1011-27
   PubMed Web of Science ®Google Scholar
• Kim KJ, Li B, Winer J, Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362:841-4
   PubMed Web of Science ®Google Scholar
• Delmotte P, Martin B, Paesmans M, VEGF and survival of patients with lung cancer: a systematic literature review and meta-analysis. Rev Mal Respir 2002;19:577-84
   PubMed Web of Science ®Google Scholar
• Fontanini G, Faviana P, Lucchi M, A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma. Br J Cancer 2002;86:558-63
   PubMed Web of Science ®Google Scholar
• Bremnes RM, Camps C, Sirera R. Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer 2006;51:143-58
   PubMed Web of Science ®Google Scholar
• Johnson DH, Fehrenbacher L, Novotny WF, Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184-91
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC, Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50
   PubMed Web of Science ®Google Scholar
• Hanna N, Shepherd FA, Fossella FV, Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-97
   PubMed Web of Science ®Google Scholar
• Reck M, von Pawel J, Zatlouka P, Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009;27:1227-34
   PubMed Web of Science ®Google Scholar
• Reck M, Kaiser R, Eschbach C, A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer. Ann Oncol 2011;22:1374-81
   PubMed Web of Science ®Google Scholar
• Reck M, von Pawel J, Zatloukal P, Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 2010;21:1804-9
   PubMed Web of Science ®Google Scholar
• Socinski MA, Langer CJ, Huang JE, Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol 2009;27:5255-61
   PubMed Web of Science ®Google Scholar
• Patel JD, Hensing TA, Rademaker A, Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol 2009;27:3284-9
   PubMed Web of Science ®Google Scholar
• Crino L, Dansin E, Garrido P, Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase IV study. Lancet Oncol 2010;11:733-40
   PubMed Web of Science ®Google Scholar
• Patel JD, Bonomi P, Socinski MA, Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. Clin Lung Cancer 2009;10:252-6
   PubMed Web of Science ®Google Scholar
• Wakelee HA, Dahlberg SE, Keller SM, Interim report of on-study demographics and toxicity from E1505, a phase III randomized trial of adjuvant (adj) chemotherapy (chemo) with or without bevacizumab (B) for completely resected early-stage non-small cell lung cancer (NSCLC). J Clin Oncol 2011;29:abstract 7013
   Google Scholar
• Miller VA, O'Connor P, Soh C, Kabbinavar FF. A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2009;27:abstract LBA8002
   Google Scholar
• Kabbinavar FF, Miller VA, Johnson BE, Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotnib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small-cell lung cancer (NSCLC). J Clin Oncol 2010;28:abstract 7526
   Google Scholar
• Herbst RS, Prager D, Hermann R, TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5892-9
   PubMed Web of Science ®Google Scholar
• Herbst RS, Ansari R, Bustin F, Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase III trial. Lancet 2011;377:1846-54
   PubMed Web of Science ®Google Scholar
• Zhang W, Dahlberg SE, Yang D, Genetic variants in angiogenesis pathway associated with clinical outcome in NSCLC patients (pts) treated with bevacizumab in combination with carboplatin and paclitaxel: subset pharmacogenetic analysis of ECOG 4599. J Clin Oncol 2009;27:abstract 8032
   Google Scholar
• Schneider BP, Wang M, Radovich M, Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008;26:4672-8
   PubMed Web of Science ®Google Scholar
• Nimeiri HS, Oza AM, Morgan RJ, Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California phase II Consortia. Gynecol Oncol 2008;110:49-55
   PubMed Web of Science ®Google Scholar
• Dahlberg SE, Sandler AB, Brahmer JR, Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J Clin Oncol 2010;28:949-54
   PubMed Web of Science ®Google Scholar
• Hanrahan EO, Lin HY, Kim ES, Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol 2010;28:193-201
   PubMed Web of Science ®Google Scholar
• Tamura T, Minami H, Yamada Y, A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors. J Thorac Oncol 2006;1:1002-9
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Schiller J, Schuchter LM, A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clin Cancer Res 2008;14:4836-42
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90
   PubMed Web of Science ®Google Scholar
• Schiller J, Lee JW, Hanna H, A randomized discontinuation phase II study of sorafenib versus placebo in patients with non-small cell lung cancer who have failed at least two prior chemotherapy regimens: E2501. J Clin Oncol 2008;26:abstract 8014
   Google Scholar
• Blumenschein GR Jr, Gatzemeier U, Fossella F, Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J Clin Oncol 2009;27:4274-80
   PubMed Web of Science ®Google Scholar
• Adjei AA, Blumenschein GR Jr, Mandrekar S, Long-term safety and tolerability of sorafenib in patients with advanced non-small-cell lung cancer: a case-based review. Clin Lung Cancer 2011;12:212-17
   PubMedGoogle Scholar
• Scagliotti G, von Pawel J, Reck M, Sorafenib plus carboplatin/paclitaxel in chemonaiive patients with stage IIIB-IV non-small cell lung cancer: interim analysis results from the phase III, randomized, double-blind, placebo-controlled, ESCAPE (Evaluation of Sorafenib, Carboplaitn and Paclitaxel Efficacy in NSCLC) trial. J Thorac Oncol 2008;3:687
   Google Scholar
• Gatzemeier U, Eisen T, Santoro A, Sorafenib (S) + Gemcitabine/Cisplatin (GC) vs GC alone in the first-line treatment of advanced non-small cell lung cancer (NSCLC): phase III NSCLC Research Experience Utilizing Sorafenib (NEXUS) Trial [abstract 3834]. 35th ESMO Congress; 8 – 12 October 2010; Milan, Italy; 2010
   Google Scholar
• Spigel DR, Burris HA III, Greco FA, Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer. J Clin Oncol 2011;29:2582-9
   PubMed Web of Science ®Google Scholar
• Gridelli C, Morgillo F, Favaretto A, Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study. Ann Oncol 2011;22:1528-34
   PubMed Web of Science ®Google Scholar
• Kim ES, Herbst RS, Wistuba II, The BATTLE Trial: personalizing therapy for lung cancer. Cancer Discov 2011;1:44-53
   PubMed Web of Science ®Google Scholar
• Ciardiello F, Caputo R, Damiano V, Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 2003;9:1546-56
   PubMed Web of Science ®Google Scholar
• Holden SN, Eckhardt SG, Basser R, Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol 2005;16:1391-7
   PubMed Web of Science ®Google Scholar
• Heymach JV, Paz-Ares L, De Braud F, Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 2008;26:5407-15
   PubMed Web of Science ®Google Scholar
• Herbst RS, Sun Y, Eberhardt WE, Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase III trial. Lancet Oncol 2010;11:619-26
   PubMed Web of Science ®Google Scholar
• de Boer RH, Arrieta O, Yang CH, Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. J Clin Oncol 2011;29:1067-74
   PubMed Web of Science ®Google Scholar
• Socinski MA, Novello S, Brahmer JR, Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 2008;26:650-6
   PubMed Web of Science ®Google Scholar
• Novello S, Scagliotti GV, Rosell R, Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer. Br J Cancer 2009;101:1543-8
   PubMed Web of Science ®Google Scholar
• Cancer and Leukemia Group B, National Cancer Institute (NCI). Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer. ClinicalTrials.gov NCT00698815. Available from: http://clinicaltrials.gov/ct2/show/NCT00698815?term=NCT00698815&rank=1
   Google Scholar
• Cancer and Leukemia Group B, National Cancer Institute (NCI). Sunitinib as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy. ClinicalTrials.gov NCT00693992. Available from: http://clinicaltrials.gov/ct2/show/NCT00693992?term=NCT00693992&rank=1
   Google Scholar
• Goss GD, Arnold A, Shepherd FA, Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study. J Clin Oncol 2010;28:49-55
   PubMed Web of Science ®Google Scholar
• NCIC Clinical Trials Group. Cediranib, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer. ClinicalTrials.gov NCT00795340. Available from: http://clinicaltrials.gov/ct2/show/NCT00795340?term=NCT00795340&rank=1
   Google Scholar
• Barbara Ann Karmanos Cancer Institute, National Cancer Institute (NCI). AZD2171 and Pemetrexed Disodium in Treating Patients With Relapsed Non-Small Cell Lung Cancer. ClinicalTrials.gov NCT00410904. Available from: http://clinicaltrials.gov/ct2/show/NCT00410904?term=NCT00410904&rank=1
   Google Scholar
• GlaxoSmithKline. Study of Pazopanib and Pemetrexed in Advanced Non-small Cell Lung Cancer. ClinicalTrials.gov NCT00871403. Available from: http://clinicaltrials.gov/ct2/show/NCT00871403?term=NCT00871403&rank=1
   Google Scholar
• Sarah Cannon Research Institute, GlaxoSmithKline, OSI Pharmaceuticals. Randomized, Double-Blind, Erlotinib/Pazopanib or Erlotinib/Placebo, Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer(NSCLC). ClinicalTrials.gov NCT01027598. Available from: http://clinicaltrials.gov/ct2/show/NCT01027598?term=NCT01027598&rank=1
   Google Scholar
• GlaxoSmithKline. Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung Cancer. ClinicalTrials.gov NCT00866528. Available from: http://clinicaltrials.gov/ct2/show/NCT00866528?term=NCT00866528&rank=1
   Google Scholar
• Polverino A, Coxon A, Starnes C, AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res 2006;66:8715-21
   PubMed Web of Science ®Google Scholar
• Blumenschein GR Jr, Kabbinavar F, Menon H, A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer. Ann Oncol 2011;22:2057-67
   PubMed Web of Science ®Google Scholar
• Scagliotti G, Vynnychenko I, Ichinose Y, An international, randomized, placebo-controlled, double-blind phase III study (MONET1) of motesanib plus carboplatin/paclitaxel (C/P) in patients with advanced nonsquamous non-small cell lung cancer (NSCLC). J Clin Oncol 2011;29:abstract LBA7512
   Google Scholar
• Schiller JH, Larson T, Ou SH, Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study. J Clin Oncol 2009;27:3836-41
   PubMed Web of Science ®Google Scholar
• Pfizer. A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer. ClinicalTrials.gov NCT00600821. Available from: http://clinicaltrials.gov/ct2/show/NCT00600821?term=NCT00600821&rank=1
   Google Scholar
• Pfizer. Evaluation Of The Efficacy Of The Combination Of Axitinib With Pemetrexed And Cisplatin In The Treatment Of Non-Squamous Non-Small Cell Lung Cancer. ClinicalTrials.gov NCT00768755. Available from: http://clinicaltrials.gov/ct2/show/NCT00768755?term=axitinib+cisplatin+pemetrexed&rank=1
   Google Scholar
• Pfizer. Trial Of AG-013736, Cisplatin, And Gemcitabine For Patients With Squamous Non-Small Cell Lung Cancer. ClinicalTrials.gov NCT00735904. Available from: http://clinicaltrials.gov/ct2/show/NCT00735904?term=NCT00735904&rank=1
   Google Scholar
• Boehringer Ingelheim Pharmaceuticals. LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer ClinicalTrials.gov NCT00805194. Available from: http://clinicaltrials.gov/ct2/show/NCT00805194
   Google Scholar
• Boehringer Ingelheim Pharmaceuticals. Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC ClinicalTrials.gov NCT00806819. Available from: http://clinicaltrials.gov/ct2/show/NCT00806819?term=NCT00806819&rank=1
   Google Scholar
• Yakes FM, Chen J, Tan J, Cabozantinib (XL 184), a novel MET and VEGFR2 inhibitor, simultanously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 2011;10:2298-308
   PubMed Web of Science ®Google Scholar
• Wakelee HA, Gettinger SN, Engelman JA, A phase Ib/II study of XL184 (BMS 907351) with and without erlotinib (E) in ptatients (pts) with non-small cell lung cancer (NSCLC). J Clin Oncol 2010;28; abstract 3017
   Google Scholar
• Van Cutsem E, Tabernero J, Lakomy R, Intravenous (IV) aflibercept versus placebo in combination with irinotecan/5-FU (FOLFIRI) for second-line treatment of metastatic colorectal cancer (MCRC): results of a multinational phase III trial (EFC10262-VELOUR) [abstract 0-0024]. 13th ESMO World Congress on Gastrointestinal Cancer; 22 – 25 June 2011; Barcelona, Spain; 2011
   Google Scholar
• Leighl NB, Raez LE, Besse B, A multicenter, phase II study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lung. J Thorac Oncol 2010;5:1054-9
   PubMedGoogle Scholar
• Novello S, Ramlau R, Gorbunova VA, Aflibercept in combination with docetaxel for second-line treatment of locally advanced or metastatic non-small-cell lung cancer (NSCLC): final results of a multinational placebo-controlled phase III trial (EFC10261-VITAL) [abstract O43.06]. 14th Biennial World Conference on Lung Cancer; 3 – 7 July 2011; Amsterdam, Netherlands; 2011
   Google Scholar
• McKeage MJ, Von Pawel J, Reck M, Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Br J Cancer 2008;99:2006-12
   PubMed Web of Science ®Google Scholar
• Lara PN Jr, Douillard JY, Nakagawa K, Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. J Clin Oncol 2011;29:2965-71
   PubMed Web of Science ®Google Scholar
• Garon EB, Kabbinavar FF, Neidhart JA, A randomized phase II trial of a vascular disrupting agent (VDA) fosbretabulin tromethamine (CA4P) with carboplatin (C), paclitaxel (P), and bevacizumab (B) in stage 3B/4 nonsquamous non-small cell lung cancer (NSCLC): analysis of safety and activity of the FALCON trial. J Clin Oncol 2011;29:abstract 7559
   Google Scholar
• Mita AC, Heist RS, Aren O, Phase II study of docetaxel with or without plinabulin (NPI-2358) in patients with non-small cell lung cancer (NSCLC). J Clin Oncol 2010;28:abstract 7592
   Google Scholar
• Dowlati A, Gray R, Sandler AB, Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab – an Eastern Cooperative Oncology Group Study. Clin Cancer Res 2008;14:1407-12
   PubMed Web of Science ®Google Scholar
• Hanrahan EO, Ryan AJ, Mann H, Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer. Clin Cancer Res 2009;15:3600-9
   PubMed Web of Science ®Google Scholar
• Yang F, Tang X, Riquelme E, Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy. Cancer Res 2011;71:5512-21
   PubMed Web of Science ®Google Scholar
• Zurita AJ, Jonasch E, Wang X, A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma. Ann Oncol 2012;23:46-52
   PubMed Web of Science ®Google Scholar